Q3 2023 Results
Company overview
Financial review
Conclusions
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
Neuroscience
Ophthalmology
cipargamin - PfATP4 inhibitor
NCT04675931 KARISMA (CKAE609B12201)
Malaria severe
Phase 2
Indication
Phase
Patients
252
Primary
Outcome
Measures
Arms
Intervention
Percentage of participants achieving at least 90% reduction in Plasmodium
falciparum (P. falciparum) at 12 hours [ Time Frame: Day 1 (12 Hours) ]
Arm 1: experimental, IV KAE609 Dose regimen 1
Arm 2: experimental, IV KAE609 Dose regimen 2
Arm 3: experimental, IV KAE609 Dose regimen 3
Arm 4: active comparator, IV Artesunate
Arm 5: Coartem, Standard of care
Patients with Malaria, severe
Target
Patients
Readout
Milestone(s)
2025
Publication
TBD
Appendix
Innovation: Clinical trials
Oncology
Global Health
References
Abbreviations
Other
82 Investor Relations | Q3 2023 Results
1 NOVARTIS | Reimagining MedicineView entire presentation